Article

A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2

This article summarizes key data presented during a virtual OncLive® Scientific Interchange & Workshop in which oncologists who specialize in lung cancer treatment discussed their practices for HER2 testing and the potential role of emerging antibody-drug conjugates and novel HER2-targeted small-molecule tyrosine kinase inhibitors for treatment of HER2-altered NSCLC.

Related Videos
Benjamin P. Levy, MD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Sandip P. Patel, MD
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Related Content
Limertinib for EGFR T790M+ NSCLC | Image Credit: © catalin – stock.adobe.com
January 17th 2025

Limertinib Wins Approval in China for EGFR T790M+ NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Suresh Senan, MRCP, FRCR, PhD
January 15th 2025

Durvalumab Shifts Decades-Long SOC as First FDA-Approved Immunotherapy Regimen in LS-SCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
January 13th 2025

Dato-DXd Receives FDA Priority Review in Pretreated EGFR-Mutated NSCLC

The OncFive: Top 5 Oncology Articles of the Week
January 11th 2025

The OncFive: Top Oncology Articles of the Week of 1/5